Pharma

Your Article Summary

See Latest Articles

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Cephalon, 06/22/09

Cephalon, Inc. announced results from a pivotal clinical trial of lestaurtinib in patients with relapsed acute myelogenous leukemia expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. An analysis of the study showed that patients who were treated with lestaurtinib showed similar rates of complete response but no increased benefit in overall survival, compared to those who received induction chemotherapy alone.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09

Myriad Genetics Acquires Exclusive Rights to Pancreatic Cancer Gene Patents From Johns Hopkins
Myriad, 10/16/09

Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09

See All of Research & Development